Mesoblast (ASX:MSB) has today announced it has expanded its partnership with JCR Pharmaceuticals in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of newborns who lack sufficient blood supply and oxygen to the brain or HIE.
The condition occurs in 2.5 out of 1,000 live births and can cause seizures, delayed development of motor skills and cognitive function, and cerebral palsy.
Mesoblast says In preclinical studies, the stem cells (MSCs) have been shown to have a significant positive effect on neurobehavioral outcome following HIE the injury.
JCR is marketing the allogeneic MSC product TEMCELL for the treatment of steroidrefractory acute graft versus host disease.
The license agreement has now been further expanded to provide JCR with rights to sell TEMCELL for HIE and to access Mesoblast’s broad patent portfolio for this indication.
Shares in Mesoblast (ASX:MSB) are trading 2.43 per cent higher at $1.48.